ERAS vs. BDTX, SBTX, NKTR, ATAI, NKTX, KMDA, MRSN, ADCT, VSTM, and AVIR
Should you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Black Diamond Therapeutics (BDTX), Silverback Therapeutics (SBTX), Nektar Therapeutics (NKTR), Atai Life Sciences (ATAI), Nkarta (NKTX), Kamada (KMDA), Mersana Therapeutics (MRSN), ADC Therapeutics (ADCT), Verastem (VSTM), and Atea Pharmaceuticals (AVIR). These companies are all part of the "medical" sector.
Black Diamond Therapeutics (NASDAQ:BDTX) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.
Black Diamond Therapeutics received 23 more outperform votes than Erasca when rated by MarketBeat users. Likewise, 63.93% of users gave Black Diamond Therapeutics an outperform vote while only 61.54% of users gave Erasca an outperform vote.
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 29.8% of Erasca shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Black Diamond Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 146.41%. Erasca has a consensus target price of $7.83, indicating a potential upside of 297.63%. Given Black Diamond Therapeutics' higher probable upside, analysts plainly believe Erasca is more favorable than Black Diamond Therapeutics.
Black Diamond Therapeutics' return on equity of -38.83% beat Erasca's return on equity.
In the previous week, Black Diamond Therapeutics had 8 more articles in the media than Erasca. MarketBeat recorded 14 mentions for Black Diamond Therapeutics and 6 mentions for Erasca. Erasca's average media sentiment score of 1.12 beat Black Diamond Therapeutics' score of 0.18 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.
Black Diamond Therapeutics has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.
Summary
Black Diamond Therapeutics beats Erasca on 8 of the 14 factors compared between the two stocks.
Get Erasca News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
